Itamar Medical Ltd. recently issued a statement to clarify its press release, “An Important Recognition in the US Market for the WatchPAT™ Device,” from March 16.

According to the statement, “Certain language in the press release mistakenly implies that the new AASM clinical practice guideline formally endorses Itamar Medical’s WatchPAT™ product. In fact, the new AASM guideline was solely referring to the Peripheral Arterial Tonometry (PAT) technology as technically adequate based on evidence, and not to a specific product or device manufacturer. Itamar Medical wishes to publicly and sincerely apologize for any potential misunderstanding and inconvenience this caused to the AASM, its members or their patients.”